Cytokinetics (CYTK) CEO Robert Blum joins Nicole Petallides to give an overview of the company and discusses its Aficamten trial. He talks about how the Sequoia-HCM Phase 3 clinical trial showed the best-case scenario result for obstructive hypertrophic cardiomyopathy. He goes over the future of heart disease treatment. Cytokinetics is a biopharma company with a focus on muscle activators and inhibitors as potential disease treatments. Tune in to find out more about the stock market today.
Trading 360
03 Jan 2024
SHARE
The Watch List
02 Feb 2024
Morning Trade Live
29 Feb 2024
The Watch List
05 Mar 2024
Morning Trade Live
07 Mar 2024
Market On Close
30 Jan 2024
Market On Close
06 Mar 2024